BioGenCell is developing cellular therapies designed to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The company's technology creates autologous cells, derived from the patients themselves, to repair themselves. BioGenCell's lead product, BC1, uses the company's technology to treat blood vessel insufficiency, which can cause multiple organ failure in diabetic patients. Derived from the patient's own adult stem cells, BioGenCell's easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. BioGenCell's patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (biobanking) of therapeutic cellular products for use in patient treatment.